Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rimegepant for preventive treatment of chronic migraine in adolescents aged 12 to under 18 years
CTR20251641Phase 3Active
- Sponsor
- Pfizer
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rimegepant in chronic migraine, sponsored by Pfizer. Started Jul 2025; status: active.
02
Drugs
rimegepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on CTR20251641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251641.